HK1074794A1 - The use of substituted cyanopyrrolidines for treating hyperlipidemia - Google Patents

The use of substituted cyanopyrrolidines for treating hyperlipidemia

Info

Publication number
HK1074794A1
HK1074794A1 HK05107206.0A HK05107206A HK1074794A1 HK 1074794 A1 HK1074794 A1 HK 1074794A1 HK 05107206 A HK05107206 A HK 05107206A HK 1074794 A1 HK1074794 A1 HK 1074794A1
Authority
HK
Hong Kong
Prior art keywords
treating hyperlipidemia
substituted
hyperlipidemia
methods
cyanopyrrolidines
Prior art date
Application number
HK05107206.0A
Other languages
English (en)
Inventor
David Grenville Holmes
Thomas Edward Hughes
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1074794A1 publication Critical patent/HK1074794A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK05107206.0A 2002-06-03 2005-08-18 The use of substituted cyanopyrrolidines for treating hyperlipidemia HK1074794A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38522002P 2002-06-03 2002-06-03
PCT/EP2003/005762 WO2003101448A1 (en) 2002-06-03 2003-06-02 The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases

Publications (1)

Publication Number Publication Date
HK1074794A1 true HK1074794A1 (en) 2005-11-25

Family

ID=29712145

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05107206.0A HK1074794A1 (en) 2002-06-03 2005-08-18 The use of substituted cyanopyrrolidines for treating hyperlipidemia

Country Status (26)

Country Link
US (2) US20050176806A1 (de)
EP (1) EP1513519B1 (de)
JP (2) JP2005532338A (de)
KR (1) KR20050012771A (de)
CN (2) CN101273987A (de)
AT (1) ATE422884T1 (de)
AU (2) AU2003245903B2 (de)
BR (1) BR0311535A (de)
CA (1) CA2487297C (de)
CY (1) CY1112800T1 (de)
DE (1) DE60326232D1 (de)
DK (1) DK1513519T3 (de)
EC (1) ECSP045469A (de)
ES (1) ES2321600T3 (de)
HK (1) HK1074794A1 (de)
IL (1) IL165181A (de)
MX (1) MXPA04012149A (de)
NO (1) NO333585B1 (de)
NZ (1) NZ536832A (de)
PL (1) PL210408B1 (de)
PT (1) PT1513519E (de)
RU (1) RU2362555C2 (de)
SG (1) SG154333A1 (de)
SI (1) SI1513519T1 (de)
WO (1) WO2003101448A1 (de)
ZA (1) ZA200409136B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101273987A (zh) * 2002-06-03 2008-10-01 诺瓦提斯公司 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
SI3366283T1 (sl) 2004-01-20 2021-12-31 Novartis Ag Formulacija za neposredno stiskanje in postopek
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
WO2006083214A1 (en) * 2005-02-02 2006-08-10 Astrazeneca Ab Pharmaceutical composition comprising a p2x7 receptor antagonist and a hmg-coa reductase inhibitor
WO2006116157A2 (en) 2005-04-22 2006-11-02 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-iv inhibitors
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
WO2008097535A2 (en) * 2007-02-08 2008-08-14 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
EP2108960A1 (de) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Verfahren zur Verwendung eines A G Protein-gekoppelten Rezeptors zur Identifikation von Peptid YY (PYY) Sekretagoga und nützliche Verbindungen zur Behandlung von durch (PYY) Sekretagoga modulierten Zuständen und nützliche Verbindungen zur Behandlung von Zuständen durch PYY
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
EP2556056A1 (de) 2010-04-06 2013-02-13 Arena Pharmaceuticals, Inc. Modulatoren des gpr119-rezeptors und behandlung von damit assoziierten erkrankungen
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EA021236B1 (ru) * 2012-10-03 2015-05-29 Дафот Энтерпраизес Лимитед Nα-АЦИЛЬНЫЕ ПРОИЗВОДНЫЕ АМИНОАЦИЛ-2-ЦИАНОПИРРОЛИДИНА - ИНГИБИТОРЫ ПРОЛИЛЭНДОПЕПТИДАЗЫ И ДИПЕПТИДИЛПЕПТИДАЗЫ-IV, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКИМ, ПРОТИВОГИПОКСИЧЕСКИМ, НЕЙРОПРОТЕКТОРНЫМ И УЛУЧШАЮЩИМ КОГНИТИВНЫЕ ФУНКЦИИ ДЕЙСТВИЕМ
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
JP2018507914A (ja) 2015-03-09 2018-03-22 インテクリン・セラピューティクス・インコーポレイテッド 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法
BR112019020485A2 (pt) 2017-04-03 2020-05-12 Coherus Biosciences, Inc. Agonista ppary para tratamento de paralisia supranuclear progressiva
JP2022525888A (ja) * 2019-03-22 2022-05-20 ラッシュ・ユニバーシティ・メディカル・センター リソソーム蓄積症のための、経鼻遺伝子送達と経口の桂皮酸、オレアミド、またはゲムフィブロジルとの組合せ

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2572399B1 (fr) * 1984-10-31 1987-01-16 Panmedica Sa Nouveaux derives de l'adamantanamine, leurs procedes de preparation et medicaments les contenant
DE19616486C5 (de) * 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
EP2574336A1 (de) * 1998-02-02 2013-04-03 Trustees Of Tufts College Verwendung von Dipeptidylpeptidaseinhibitoren zur Regulierung des Glucosemetabolismus
DE19828114A1 (de) * 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) * 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
EP1125922A1 (de) * 1998-11-02 2001-08-22 Welfide Corporation Pyrrolidin-verbindungen und eine medizinische anwendung dafür
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
JP4232332B2 (ja) * 1999-11-10 2009-03-04 末藏 岩田 タンク付電動床磨機用ブラシ台
DE122008000018I1 (de) * 2000-01-21 2008-08-14 Novartis Pharma Ag Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
BR0213958A (pt) * 2001-10-31 2004-09-08 Novartis Ag Métodos para tratar diabete e condições relacionadas com base em polimorfismos no gene tcf1
AR039090A1 (es) * 2002-03-22 2005-02-09 Novartis Ag Combinacion de compuestos organicos
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
CN101273987A (zh) * 2002-06-03 2008-10-01 诺瓦提斯公司 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途
US7935723B2 (en) * 2004-06-04 2011-05-03 Novartis Pharma Ag Use of organic compounds
AU2006292377B2 (en) * 2005-09-20 2011-03-03 Emisphere Technologies, Inc. Use of a DPP-IV inhibitor to reduce hypoglycemic events

Also Published As

Publication number Publication date
US20120014907A1 (en) 2012-01-19
EP1513519A1 (de) 2005-03-16
MXPA04012149A (es) 2005-04-19
CN100402026C (zh) 2008-07-16
WO2003101448A1 (en) 2003-12-11
ATE422884T1 (de) 2009-03-15
ECSP045469A (es) 2005-01-28
AU2003245903A1 (en) 2003-12-19
DK1513519T3 (da) 2009-06-02
NO333585B1 (no) 2013-07-15
US20050176806A1 (en) 2005-08-11
PT1513519E (pt) 2009-05-06
AU2006246483B9 (en) 2010-08-12
AU2003245903B2 (en) 2006-11-30
NO20045452L (no) 2005-03-01
BR0311535A (pt) 2005-02-22
CY1112800T1 (el) 2016-02-10
AU2006246483A1 (en) 2006-12-21
PL210408B1 (pl) 2012-01-31
KR20050012771A (ko) 2005-02-02
RU2004139029A (ru) 2005-08-27
SI1513519T1 (sl) 2009-06-30
SG154333A1 (en) 2009-08-28
RU2362555C2 (ru) 2009-07-27
DE60326232D1 (de) 2009-04-02
ZA200409136B (en) 2005-07-27
CN101273987A (zh) 2008-10-01
NZ536832A (en) 2006-11-30
CA2487297A1 (en) 2003-12-11
IL165181A (en) 2010-06-16
IL165181A0 (en) 2005-12-18
EP1513519B1 (de) 2009-02-18
JP2010155866A (ja) 2010-07-15
ES2321600T3 (es) 2009-06-09
JP2005532338A (ja) 2005-10-27
CA2487297C (en) 2011-08-09
PL374016A1 (en) 2005-09-19
CN1658867A (zh) 2005-08-24
AU2006246483B2 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
HK1074794A1 (en) The use of substituted cyanopyrrolidines for treating hyperlipidemia
DE60118003D1 (de) Harnstoffderivate und ihre verwendung
CA2534571A1 (en) Substituted isoquinoline derivatives and methods of use
MXPA02012034A (es) Derivados de tiofeno utiles como agentes anticancerosos.
SI1487444T1 (sl) Uporaba piridil-amidov kot inhibitorjev angiogeneze
ATE361287T1 (de) Neue indol-2-on derivate
IL152073A0 (en) Percyquinnin, a process for its production and its use as a pharmaceutical
MXPA04000328A (es) Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer.
HK1069169A1 (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
MY126917A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
MXPA03011954A (es) Nuevos derivados de acido sulfonico.
TW200716597A (en) Novel piperidine-substituted indoles
TW200730177A (en) 4 anilino-3-quinolinecarbonitriles for the treatment of cancer
MXPA04000485A (es) Uso de acidos aril o heteroaril hidroxamicos de sulfonilo y derivados de los mismos como inhibidores de agrecanasa.
MY143862A (en) Piperidine-substituted indoles-or heteroderivatives thereof
EP1057829A4 (de) Kondensierte Pyrimidinderivate und diese enthaltende pharmazeutische Zubereitungen
EP0802179A4 (de) Derivate substituierter amidinonaphthylester
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them
DK0706796T3 (da) Dopamingenoptagelsesinhibitorer til behandling af parkinsonisme

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140602